Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR168 in Refractory Lupus Nephritis
NCT07729826Phase 2Not yet recruiting
- Sponsor
- AbelZeta
- Start
- Sep 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label, single-arm trial of C-CAR168 in lupus nephritis (LN), sponsored by AbelZeta. Primary endpoint: Complete Renal Response at 65 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
C-CAR168
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07729826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729826.